

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. § 208(b)(3)

David Schoenfeld, Ph.D.

Committees: Joint Nonprescription Drugs Advisory Committee and Pulmonary Allergy Drugs Advisory Committee Meeting

Meeting Dates: January 24, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to agenda item, discussions of the continued need for the designation of over-the-counter (OTC) epinephrine-metered dose inhalers (MDIs) for the treatment of asthma as an essential use of ozone-depleting substances under 21 CFR 2.125, I am eligible to receive a waiver under 18 U.S.C. § 208(b)(3).

Type of Interest	Nature	Magnitude
Co-founder and part owner Of a Clinical Research Organization	Unrelated contract with 2 firms affected by the OTC epinephrine-MDIs discussions	Less than \$10,001 per year from one firm and from \$10,001 to \$50,000 per year from another firm
Consulting	Company affected by the OTC epinephrine-MDIs discussions	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

Signature of SGE

12/21/05

Date